shutterstock-128145248-web

Adam Gregor / Shutterstock.com

31 July 2014Americas

Pfizer acquires Baxter vaccines for $635m

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More on this story

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More on this story

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York